COR2ED Medical Education
@cor2ed.com
COR2ED develops high-quality Independent Medical Education programmes for HCPs globally.
Visit our website: https://cor2ed.com/
Read the Community Guidelines: https://t.co/KZbQi7TR4U
#MedEd #IME #MedicalEducation
Visit our website: https://cor2ed.com/
Read the Community Guidelines: https://t.co/KZbQi7TR4U
#MedEd #IME #MedicalEducation
Closing the Gap in HPP Care 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
November 17, 2025 at 9:03 AM
Closing the Gap in HPP Care 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
webapp.spotme.com/login/alexio...
📅 2 & 4 December | Live sessions
Initiated and funded by Alexion, AstraZeneca Rare Disease and brought to you in collaboration with COR2ED Medical Affairs. Intended for healthcare professionals only. M/GL/Med HPP/0096 | Nov 2025
Today is #WorldHPPDay
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
October 30, 2025 at 9:19 AM
Today is #WorldHPPDay
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
#Hypophosphatasia (HPP) is a #RareDisease that can impact working, connecting, and living independently
In the video (GL/UNB-H/0096), Suzanne & Amy share their HPP stories 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0095
Rethinking HPP (hypophosphatasia)
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
October 23, 2025 at 10:40 AM
Rethinking HPP (hypophosphatasia)
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
➡️ HPP is an inherited disorder that can impact a patient’s ability to work, connect, and live independently
Watch the video (GL/UNB-H/0087) for key facts 📺
This material has been initiated and funded by Alexion Pharmaceuticals. 10/2025 GL/UNB-H/0091
#RareDiseases
How can new clinical trials in radioligand therapy impact clinical practice in #NET treatment strategies?
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
October 6, 2025 at 3:00 PM
How can new clinical trials in radioligand therapy impact clinical practice in #NET treatment strategies?
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
Find out in this new #MedEd video from medical experts
cor2ed.com/net-connect/...
Supported by an Independent Educational Grant from ITM
@nanets.bsky.social #MedSky #medicaleducation 📷
🔎 Expert insights on recent #BreastCancer data
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
July 8, 2025 at 10:25 AM
🔎 Expert insights on recent #BreastCancer data
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social
Dr Paolo Tarantino discusses data from SERENA-6, ASCENT-04/KEYNOTE-D19 & DESTINY-Breast09 studies presented at #ASCO25
Watch his video & see more ASCO updates
▶️ cor2ed.com/n-connect/pr...
Supported by COR2ED #MedEd #MedSky @ptarantinomd.bsky.social